Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes

Article

PRESS RELEASE

PARIS

and

MOUNTAIN VIEW, Calif.

,

Aug. 31, 2015

/PRNewswire/ -- Sanofi (NYSE: SNY; EURONEXT: SAN) and the life sciences team at Google announced today that they are collaborating to improve care and outcomes for people with type 1 and type 2 diabetes. The collaboration will pair Sanofi's leadership in diabetes treatments and devices with Google's expertise in analytics, miniaturized electronics and low power chip design. The companies will explore how to improve diabetes care by developing new tools that bring together many of the previously siloed pieces of diabetes management and enable new kinds of interventions. This includes health indicators such as blood glucose and hemoglobin A1c levels, patient-reported information, medication regimens and sensor devices.

Sanofi and the life sciences team at Google will combine their respective expertise in science and technology to work on better ways to collect, analyze and understand multiple sources of information impacting diabetes. The hope is that it will be easier for patients to successfully manage their diabetes, which would reduce the risk of complications, improve outcomes and ultimately lower costs.

"As a global leader in diabetes care, we have both an obligation and a commitment to provide integrated solutions for people living with diabetes," said

Olivier Brandicourt

, MD, Chief Executive Officer, Sanofi. "This initiative combines Sanofi's strength and knowledge in diabetes with Google's leadership in technology and analytics to create a first-of-its-kind initiative with the potential to transform diabetes care."

"With new technologies emerging to provide a more continuous and real-time view of a patient's health, we can see the promise for more proactive and effective ways to control diabetes," said

Andy Conrad

, CEO of the life sciences team at Google. "Together with Sanofi, we believe diabetes management can be simpler and more convenient, which may help patients achieve an improved quality of life."

"We have built expertise in providing holistic, integrated solutions that combine medicines, devices, technologies and services," said

Pascale Witz

, Executive Vice President, Sanofi, who will lead the Global Diabetes and Cardiovascular Care Business Unit in the company's new organizational structure. "The life sciences team at Google can help us improve the patient experience, outcomes and manage healthcare costs more effectively."

"We are experiencing a worldwide pandemic of diabetes, and it's very encouraging to see healthcare and technology innovators step up to the challenge of providing cutting edge tools and care advancing technologies to help people with diabetes manage their disease, 24/7," said

John L. Brooks, III

, President and CEO of Joslin Diabetes Center, which is a partner to the collaboration. "Technology, sensors, analytics, and digital solutions will revolutionize how blood sugars are managed, which will deliver improved quality of life, lowering the risk of complications and reducing the costs and barriers associated with diabetes care. Ultimately, I truly hope we're able to turn the Joslin Diabetes Center into a museum."

Related Videos
Image credit: Melita - stock.adobe.com
Atopic dermatitis on a patient's hand -- Image credit: Ольга Тернавская | stock.adobe.com
cropped view of man performing chest compression on dummy during cpr training class - Image credit: LIGHTFIELD STUDIOS | stock.adobe.com
Medicine law concept. Judges gavel with pills | Image Credit: Iren Moroz - stock.adobe.com
Image credit: New Africa | stock.adobe.com
biosimilar word or concept represented by wooden letter tiles on a wooden table with glasses and a book | Image Credit: lexiconimages - stock.adobe.com
Image credit: alicja neumiler | stock.adobe.com
Laboratory test tubes and solution with stethoscope background | Image Credit: Shutter2U - stock.adobe.com
© 2024 MJH Life Sciences

All rights reserved.